NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
Clinical Trials
54 trialsNCT03541486 2025-03-10
XACT-PANC-2
University of Iowa
Phase 2 Withdrawn
NCT02428764 2024-12-10
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
Sun Yat-sen University
Phase 2 Withdrawn
NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT04183062 2024-11-08
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Phase 2 Withdrawn
NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT06017323 2023-10-25
ProglumidePanc
Georgetown University
Phase 1 Withdrawn
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT01971489 2023-04-27
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05431244 2022-11-01
Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)
Samsung Medical Center
Phase NA Withdrawn
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT05212025 2022-06-14
Adavosertib and Gemcitabine in Advanced Pancreatic
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT04230330 2020-11-05
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
National Cancer Centre, Singapore
Phase 1 Withdrawn
NCT00226746 2020-09-18
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
New York Presbyterian Brooklyn Methodist Hospital
Phase 2 Withdrawn
NCT03579758 2020-06-05
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
Phase 3 Withdrawn
NCT04134468 2020-01-31
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT01524575 2019-09-25
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
University of Hawaii
Phase 2 Withdrawn
NCT03697239 2019-06-11
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
University of California, San Diego
Phase 1/2 Withdrawn
NCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02534337 2019-06-04
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT03797443 2019-05-31
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
Phase 1/2 Withdrawn
NCT03908333 2019-05-30
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT03392571 2019-05-07
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
Pancreatic Cancer Research Team
Phase 2 Withdrawn
NCT02105350 2018-02-19
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
University Health Network, Toronto
Phase 1 Withdrawn
NCT02944357 2017-11-17
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Mayo Clinic
Phase NA Withdrawn
NCT02405910 2017-11-06
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
West Virginia University
Phase 2 Withdrawn
NCT02961816 2017-04-21
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT01045941 2016-10-06
Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT00951444 2016-07-06
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT02701673 2016-05-04
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02537561 2016-02-11
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Washington University School of Medicine
Phase 1 Withdrawn
NCT01598584 2015-09-28
Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Withdrawn
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT02159248 2015-04-28
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Orlando Health, Inc.
Phase 1 Withdrawn
NCT02048943 2015-01-09
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT01336543 2014-12-18
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
Louisiana State University Health Sciences Center Shreveport
Phase 2 Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00014287 2013-12-19
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
University of Pittsburgh
Phase 1 Withdrawn
NCT00005591 2013-12-13
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00524069 2013-02-01
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Roswell Park Cancer Institute
Phase NA Withdrawn